

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page3/line41	Abstract/Para1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page3/line42-65	Abstract/Para2-4
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page5-6/line70-103	Introduction/Para1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page6/line104-107	Introduction/Para4
Methods				
Study design	4	Present key elements of study design early in the paper	Page7/line104-106	Methods/Para2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page7-11/line115-147	Methods/Para2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Page8/line123-147, Page10/line173-200	Methods/Para2 Methods/Para6
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls		
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants		
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	-	-
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page10/line182-193 Page9/line158-171	Methods/Para4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page8-9/line148-171	Methods/Para3-5
Bias	9	Describe any efforts to address potential sources of bias	Page10-11/line193-199	Methods/Para6
Study size	10	Explain how the study size was arrived at	Page7-8/line121-147	Methods/Para2

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page8-9/line148-171	Methods/Para3-5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page11/line202-206	Methods/Para7
		(b) Describe any methods used to examine subgroups and interactions	Page11/line207-216	Methods/Para7
		(c) Explain how missing data were addressed	Page11/line 209-210	Methods/Para7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Page11/line 209-210	Methods/Para7
		(e) Describe any sensitivity analyses	Page11/line217-219	Methods/Para7
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure S1	Figure S1
		(b) Give reasons for non-participation at each stage	Figure S1	Figure S1
		(c) Consider use of a flow diagram	Figure S1	Figure S1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page12/line227-238	Results/Para1
		(b) Indicate number of participants with missing data for each variable of interest	Page12/line227-238	Results/Para1
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Page12-13/line238-241	Results/Para1
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Page13/line243-250	Results/Para2
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page13/line251-271	Results/Para3-4
		(b) Report category boundaries when continuous variables were categorized	Page9/line147-157	Methods/Para3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page13-14/line261-262	Results/Para4

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page13-14/line257-273	Results/Para4-4
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page14/line275-280	Discussion/Para1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page15/line292-308	Discussion/Para3
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page15-17/line309-348	Discussion/Para4-5
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page15/line297-299	Discussion/Para3
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page17-18/line360-362	funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: <https://dx.doi.org/10.21037/cdt-23-284>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.